Cogent Biosciences, Inc. — 2018 Q3 filing summary
Registrant identity: The supplied Form 10-Q is for Unum Therapeutics Inc., not Cogent Biosciences, Inc. It covers the quarter ended September 30, 2018 and was filed November 13, 2018. The summary below reflects the filing provided.
Business context and reporting period
Unum was a clinical-stage biopharmaceutical company developing engineered T-cell cancer therapies using its ACTR and BOXR platforms. It had no approved products and no product-sale revenue; reported revenue came from its Seattle Genetics collaboration. The statements are unaudited.
In April 2018, Unum completed an IPO and concurrent private placement, and its preferred stock converted to common stock. The company selected ACTR707 plus rituximab as its lead lymphoma candidate and planned to wind down enrollment in the ACTR087 plus rituximab study during the first half of 2019.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. The filing reports no product gross profit or gross margin; a product margin is not meaningful because the company had no product sales.
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Collaboration revenue | $2.0 | $2.3 | $5.9 | $6.2 |
| Research and development | $10.3 | $8.2 | $27.5 | $22.3 |
| General and administrative | $2.4 | $1.3 | $5.4 | $3.2 |
| Total operating expenses | $12.6 | $9.5 | $32.9 | $25.5 |
| Operating loss | $(10.6) | $(7.2) | $(27.0) | $(19.3) |
| Net loss | $(10.2) | $(7.0) | $(25.9) | $(18.8) |
| Net loss per share, basic and diluted | $(0.34) | $(0.69) | $(1.12) | $(1.85) |
- At September 30, 2018, cash and cash equivalents were $49.3 million and marketable securities were $37.8 million, totaling $87.1 million. Current assets were $89.5 million and current liabilities were $26.4 million; working capital was $63.1 million.
- Cash used in operating activities was $23.5 million for the first nine months, versus $19.3 million in 2017. Investing activities used $25.5 million, primarily reflecting net purchases of marketable securities; financing activities provided $70.0 million, principally from the IPO and concurrent private placement.
- No loan borrowings were outstanding. The company had up to $15.0 million available under its Pacific Western Bank facility, secured by substantially all assets other than intellectual property.
- Total liabilities were $27.3 million. There was no conventional debt outstanding at quarter-end; deferred revenue was $20.1 million, and the bank facility remained undrawn.
Changes versus the prior comparable period
- Q3 revenue decreased 12%, while operating expenses rose 33%; net loss widened by $3.2 million. For the nine-month period, revenue fell 5%, operating expenses rose 29%, and net loss widened by $7.1 million.
- R&D increases reflected clinical-trial and manufacturing spending for ACTR707 plus rituximab and ACTR087 plus SEA-BCMA, increased facility and manufacturing-process costs, and higher personnel and stock-based compensation. Lower ACTR087 plus rituximab manufacturing activity partly offset the increases.
- G&A growth reflected public-company costs, including professional and consulting fees, insurance, and personnel-related expense.
- Comparisons of 2018 collaboration revenue with 2017 are affected by adoption of ASC 606 on January 1, 2018. Under ASC 606, revenue is recognized using a cost-to-cost method rather than straight-line recognition. For 2018, the filing shows revenue $0.8 million lower for Q3 and $2.2 million lower year to date under ASC 606 than it would have been under the prior standard. Adoption also increased opening deferred revenue and accumulated deficit by $6.2 million.
- The IPO and private placement substantially increased cash and common shares outstanding. The filing reports 29.9 million common shares outstanding at September 30 and 29,989,472 at October 31, 2018.
Outlook, risks and unusual items
- Management expected cash, cash equivalents, and marketable securities to fund operating expenses and capital requirements through at least June 2020, excluding available bank borrowings. The notes separately say resources were expected to last at least 12 months from the November 13, 2018 issuance date; investors should reconcile these runway statements.
- The company expected significant future losses and rising expenses as it advanced clinical programs and operated as a public company. It stated that additional financing would ultimately be needed and warned that it might not be available on acceptable terms.
- Clinical updates and plans: enrollment had reached the third dose level in the ACTR707 plus rituximab Phase I trial, with additional data expected at the December 2018 ASH meeting. Initial ACTR087 plus SEA-BCMA data were also expected at ASH. The company expected to start a Phase I ACTR707 plus trastuzumab trial by year-end 2018.
- Safety was a material risk. In the ACTR087 plus rituximab study, two of 17 treated patients had ACTR087-related severe cytokine release syndrome and one had ACTR087-related neurotoxicity that was fatal. The trial had been placed on FDA clinical hold in December 2017; the hold was removed in February 2018 after the company submitted information. The filing warns that serious adverse events could recur or prompt further holds.
- Additional risks include early-stage clinical uncertainty, manufacturing and supply constraints, dependence on third parties and collaboration partners, need for additional capital, regulatory approval uncertainty, and limited intellectual-property protection. The company disclosed $1.5 million in non-cancelable manufacturing commitments over the following 12 months and approximately $9.0 million in future minimum operating-lease payments.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls at September 30, 2018. Management said adoption of the forthcoming lease standard was expected to result in material right-of-use assets and liabilities.
Most important facts for investors to verify
- Confirm that this Unum Therapeutics filing—not a Cogent Biosciences filing—is the intended source.
- Reconcile the stated cash runway through June 2020 with the notes’ “at least 12 months” estimate from November 13, 2018, and review cash burn against clinical spending plans.
- Review updated clinical data, especially safety and efficacy in the ACTR707 lymphoma trial, and the status of the ACTR087 trial after its clinical hold and planned enrollment conclusion.
- Assess how ASC 606 affects collaboration revenue, deferred revenue, and period-to-period comparisons; the filing estimates $71.3 million allocated to remaining Seattle Genetics performance obligations through 2022.
- Track financing needs and potential dilution, the undrawn secured credit facility’s terms, and manufacturing capacity and supplier commitments.